OA10213A - Oral treatment of helicobacter infection - Google Patents

Oral treatment of helicobacter infection Download PDF

Info

Publication number
OA10213A
OA10213A OA60449A OA60449A OA10213A OA 10213 A OA10213 A OA 10213A OA 60449 A OA60449 A OA 60449A OA 60449 A OA60449 A OA 60449A OA 10213 A OA10213 A OA 10213A
Authority
OA
OAPI
Prior art keywords
iga
felis
infection
antigen
host
Prior art date
Application number
OA60449A
Other languages
English (en)
Inventor
Czinn Steven James
Nedrud John Gilbert
Original Assignee
Czinn Steven James
Nedrud John Gilbert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25351374&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA10213(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Czinn Steven James, Nedrud John Gilbert filed Critical Czinn Steven James
Publication of OA10213A publication Critical patent/OA10213A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/121—Helicobacter (G); Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
OA60449A 1992-04-13 1993-12-13 Oral treatment of helicobacter infection OA10213A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86828692A 1992-04-13 1992-04-13

Publications (1)

Publication Number Publication Date
OA10213A true OA10213A (en) 1997-10-07

Family

ID=25351374

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60449A OA10213A (en) 1992-04-13 1993-12-13 Oral treatment of helicobacter infection

Country Status (17)

Country Link
US (1) US5538729A (fr)
EP (1) EP0590138A4 (fr)
JP (1) JPH07500845A (fr)
BG (1) BG61935B1 (fr)
BR (1) BR9305482A (fr)
CA (1) CA2111189A1 (fr)
CZ (1) CZ273093A3 (fr)
FI (1) FI935591A7 (fr)
HU (1) HU214699B (fr)
MX (1) MX9301706A (fr)
NO (1) NO934547D0 (fr)
NZ (1) NZ251849A (fr)
OA (1) OA10213A (fr)
RU (1) RU2107513C1 (fr)
SG (1) SG52556A1 (fr)
SK (1) SK281238B6 (fr)
WO (1) WO1993020843A1 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2682122B1 (fr) * 1991-10-03 1995-06-09 Pasteur Institut Nouveaux genes d'helicobacter pylori. leur utilisation pour la preparation de souches recombinantes de h. pylori.
CA2117490C (fr) * 1992-02-26 2009-01-06 Timothy L. Cover Toxine vacuolisante purifiee de helicobacter pylori et methodes d'utilisation
US7141244B1 (en) * 1992-03-02 2006-11-28 Chiron Srl Helicobacter pylori proteins useful for vaccines and diagnostics
MX9301706A (es) * 1992-04-13 1994-05-31 Oravax Inc Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
US6290962B1 (en) * 1992-11-03 2001-09-18 Oravax, Inc. Urease-based vaccine and treatment for helicobacter infection
US5972336A (en) * 1992-11-03 1999-10-26 Oravax Merieux Co. Urease-based vaccine against helicobacter infection
US6258359B1 (en) 1993-05-19 2001-07-10 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides
JPH08509873A (ja) 1993-05-19 1996-10-22 アンスティテュ・パストゥール ヘリコバクター感染に対する免疫組成物、該組成物に用いられるポリペプチドおよび該ポリペプチドをコードする核酸配列
US5871749A (en) * 1993-07-27 1999-02-16 Csl Limited Therapeutic treatment of H. pylori associated gastroduodenal disease
US6406703B1 (en) 1993-07-27 2002-06-18 Csl Limited Treatment of H. pylori associated gastroduodenal disease
AUPM399594A0 (en) 1994-02-21 1994-03-17 Csl Limited Antigenic preparation for treatment or prevention of helicobacter infection
AUPM612494A0 (en) * 1994-06-08 1994-06-30 Csl Limited Treatment or prevention of helicobacter infection
AU702878B2 (en) * 1994-06-08 1999-03-11 Csl Limited Treatment and prevention of helicobacter infection
US5780040A (en) * 1994-06-08 1998-07-14 Tufts University School Of Medicine Hospital, Inc. Helicobacter pylori nickel binding protein
JPH10502366A (ja) * 1994-07-01 1998-03-03 リカン・リミテッド ヘリコバクター・ピロリ抗原タンパク質調製品およびイムノアッセイ
ATE310803T1 (de) * 1994-10-05 2005-12-15 Antex Biolog Inc Verfahren zur produktion von verstärkt antigen wirkenden heliobacter sp. und vakzine die diesen enthalten
US5897475A (en) * 1994-10-05 1999-04-27 Antex Biologics, Inc. Vaccines comprising enhanced antigenic helicobacter spp.
FR2732605B1 (fr) * 1995-04-07 1997-05-16 Pasteur Merieux Serums Vacc Composition destinee a l'induction d'une reponse immunitaire mucosale
AR003125A1 (es) * 1995-06-01 1998-07-08 Astra Ab Antigenos bacterianos para el diagnostico de infecciones con helicobacter pylori, una molecula de adn que lo codifica, un vector, una celula huesped,procedimiento para producir el polipeptido, composiciones para vacunas adecuadas para uso terapeutico y profilactico, el uso del polipeptido en la
WO1997013784A1 (fr) * 1995-10-09 1997-04-17 Pasteur Merieux Serums Et Vaccins Recepteur lactoferrine d'helicobacter
GB2307987A (en) * 1995-12-06 1997-06-11 Univ Manchester Epitopes of the urease of Helicobacter pylori as dignostic agents; pharmaceuticals comprising such epitopes or the antibodies thereto
JP2000502257A (ja) * 1995-12-19 2000-02-29 アイオワ ステート ユニバーシティー リサーチ ファウンデーション，インコーポレーテッド ヘテロフィル適合化家禽用ワクチン
GB2324093A (en) * 1996-01-04 1998-10-14 Rican Limited Helicobacter pylori bacterioferritin
NZ333250A (en) * 1996-06-10 2000-05-26 Thomas Boren Helicobacter pylori blood group antigen binding adhesion protein
US20030124141A1 (en) * 1997-04-01 2003-07-03 Rainer Haas Helicobacter polypeptides and corresponding polynucleotide molecules
EP0980204A4 (fr) * 1997-04-01 2005-06-15 Merieux Oravax POLYPEPTIDES D'HELICOBACTER DE 76 kDa, 32 kDa ET 50 kDa ET MOLECULES DE POLYNUCLEOTIDES CORRESPONDANTES
US20020026035A1 (en) * 1997-04-01 2002-02-28 Harold Kleanthous Helicobacter ghpo 1360 and ghpo 750 polypeptides and corresponding polynucleotide molecules
JP3430853B2 (ja) 1997-04-11 2003-07-28 株式会社ゲン・コーポレーション 胃炎、胃潰瘍および十二指腸潰瘍の予防剤並びに治療剤
SE9702240D0 (sv) * 1997-06-12 1997-06-12 Astra Ab Vaccine compositions III
KR100509817B1 (ko) * 1997-06-27 2005-12-16 씨제이 주식회사 비브리오불니피쿠스의감염예방을위한경구용백신
US20030158396A1 (en) * 1997-07-29 2003-08-21 Harold Kleanthous Identification of polynucleotides encoding novel helicobacter polypeptides in the helicobacter genome
US6599509B2 (en) 1997-09-02 2003-07-29 Massachusetts Institute Of Technology Compositions and methods comprising helicobacter antigens for treatment and prevention of inflammatory bowel disease
US5985631A (en) * 1997-09-12 1999-11-16 Oravax-Merieux Co. Method for preventing the activation of inactive, recombinant Helicobacter pylori apourease
SE9801288D0 (sv) 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and metod of production
US6585975B1 (en) * 1998-04-30 2003-07-01 Acambis, Inc. Use of Salmonella vectors for vaccination against helicobacter infection
US6576244B1 (en) 1998-06-19 2003-06-10 Acambis, Inc. LT and CT in parenteral immunization methods against helicobacter infection
US7087236B1 (en) 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
RU2182486C2 (ru) * 2000-04-25 2002-05-20 Юсупов Гамзат Абдуллаевич Способ лечения язвенной болезни двенадцатиперстной кишки и лекарственный препарат для его осуществления
US20020107368A1 (en) * 2000-12-07 2002-08-08 Jing-Hui Tian Helicobacter proteins, gene sequences and uses thereof
WO2003018054A1 (fr) * 2001-08-31 2003-03-06 Chiron Srl. Vaccination contre helicobacter pylori avec une combinaison de proteines caga, vaca et nap
WO2006133879A2 (fr) * 2005-06-16 2006-12-21 Universiteit Gent Vaccins d'immunisation contre helicobacter
US7790143B2 (en) * 2005-06-16 2010-09-07 Universiteit Gent Vaccines for immunization against helicobacter

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5417986A (en) * 1984-03-16 1995-05-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
US5268276A (en) * 1988-09-16 1993-12-07 Jan Holmgren Recombinant systems for expression of cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
FR2637612B1 (fr) * 1988-10-06 1993-09-10 Pasteur Institut Sequences de nucleotides codant pour une proteine a activite ureasique
DE4139840B4 (de) * 1990-12-04 2005-06-02 Quidel Corp., San Diego Antigen-Zubereitung zum Nachweis von H. pylori
CA2109088A1 (fr) 1991-04-26 1992-10-27 Emanuel Calenoff Methode de detection et de traitement de maladies causees par des allergenes bacteriens
FR2682122B1 (fr) * 1991-10-03 1995-06-09 Pasteur Institut Nouveaux genes d'helicobacter pylori. leur utilisation pour la preparation de souches recombinantes de h. pylori.
CA2117490C (fr) * 1992-02-26 2009-01-06 Timothy L. Cover Toxine vacuolisante purifiee de helicobacter pylori et methodes d'utilisation
DE69333110T2 (de) * 1992-03-02 2004-05-06 Chiron S.P.A. Mit dem cytotoxin von helicobacter pylori assoziiertes, immunodominantes antigen verwendbar in impfstoffen und zur diagnose
MX9301706A (es) * 1992-04-13 1994-05-31 Oravax Inc Composicion de vacuna para el tratamiento de la infeccion por helicobacter.

Also Published As

Publication number Publication date
HU9303561D0 (en) 1994-04-28
EP0590138A1 (fr) 1994-04-06
SK141293A3 (en) 1994-07-06
JPH07500845A (ja) 1995-01-26
EP0590138A4 (en) 1996-01-24
BR9305482A (pt) 1994-10-04
FI935591A0 (fi) 1993-12-13
RU2107513C1 (ru) 1998-03-27
HU214699B (hu) 1998-04-28
SK281238B6 (sk) 2001-01-18
HUT67058A (en) 1995-01-30
FI935591L (fi) 1994-02-11
FI935591A7 (fi) 1994-02-11
SG52556A1 (en) 1998-09-28
CA2111189A1 (fr) 1993-10-28
US5538729A (en) 1996-07-23
BG98294A (bg) 1995-02-28
WO1993020843A1 (fr) 1993-10-28
CZ273093A3 (en) 1994-04-13
AU3977093A (en) 1993-11-18
MX9301706A (es) 1994-05-31
BG61935B1 (bg) 1998-10-30
AU675938B2 (en) 1997-02-27
NZ251849A (en) 1997-06-24
NO934547D0 (no) 1993-12-10

Similar Documents

Publication Publication Date Title
OA10213A (en) Oral treatment of helicobacter infection
Czinn et al. Protection of germ-free mice from infection by Helicobacter felis after active oral or passive IgA immunization
US6419926B2 (en) Specific antibodies for use in preparation of pharmaceutical compositions useful in the prevention or treatment of gastritis, gastric ulcers and duodenal ulcers
FI112032B (fi) Menetelmä ureaasipohjaisen rokotteen valmistamiseksi Helicobacter-infektiota vastaan
NZ218499A (en) Monoclonal antibodies against pseudomonas aeruginosa, pharmaceutical compositions and detection methods
EP0804489B1 (fr) Preparation antigenique utilisable pour le traitement ou la prevention d'une infection a helicobacter
EP0702564A1 (fr) Nouvelle souche de pseudomonas aeruginosa attenuee
CS244906B2 (en) Production method of antigen agent for limitation or prevention of tooth defects
US4834976A (en) Monoclonal antibodies to pseudomonas aeruginosa flagella
JPH0526474B2 (fr)
JP2639422B2 (ja) シュードモナスアエルギノーザ鞭毛に対するモノクローナル抗体
KR910004868B1 (ko) 인체 단일 클론항체 및 그것을 활성성분으로 함유하는 감염증의 예방 및 치료용 약학적 제제
JP3635580B2 (ja) 増強された抗原性ヘリコバクターｓｐ．の作出方法およびそれを含むワクチン
EP0761819A1 (fr) Exopolysaccharides du burkholderia pseudomallei et burkholderia mallei
JPS60248626A (ja) 緑膿菌感染症の予防治療剤
AU675938C (en) Oral treatment of helicobacter infection
WO1990013660A2 (fr) Anticorps monoclonaux humains de determinants sero-specifiques de bacteries gram-negatives
JPH05504049A (ja) 新規な伝染性ファブリキウス嚢病ウイルス
JP2587770B2 (ja) 形質転換細胞
EP0450573A2 (fr) Anticorps pour le traitement et le diagnostic d'infections de Pseudomonas aeruginosa
JPS61152280A (ja) 抗緑膿菌ヒト抗体を産生する形質転換細胞及びその製造法並びにその使用方法